Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Long-Term Investments (2017 - 2025)

Corcept Therapeutics (CORT) has disclosed Long-Term Investments for 9 consecutive years, with $160.3 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 27.09% to $160.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $160.3 million through Dec 2025, down 27.09% year-over-year, with the annual reading at $160.3 million for FY2025, 27.09% down from the prior year.
  • Long-Term Investments hit $160.3 million in Q4 2025 for Corcept Therapeutics, up from $102.6 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $248.0 million in Q1 2025 to a low of $4.9 million in Q3 2022.
  • Historically, Long-Term Investments has averaged $95.6 million across 5 years, with a median of $91.7 million in 2021.
  • Biggest five-year swings in Long-Term Investments: skyrocketed 2320.4% in 2021 and later tumbled 96.34% in 2022.
  • Year by year, Long-Term Investments stood at $112.3 million in 2021, then plummeted by 95.59% to $4.9 million in 2022, then surged by 1055.77% to $57.2 million in 2023, then skyrocketed by 284.48% to $219.8 million in 2024, then decreased by 27.09% to $160.3 million in 2025.
  • Business Quant data shows Long-Term Investments for CORT at $160.3 million in Q4 2025, $102.6 million in Q3 2025, and $172.8 million in Q2 2025.